HP Inc has appointed Emma Walmsley as Chief Executive Officer, concluding a search the personal computing and printing group opened after moving to interim leadership earlier in the year. She takes up the post in early January.
The choice is an unusual one for a large American technology company. Walmsley is not a career technologist. She led GSK, the British pharmaceuticals and vaccines group, as chief executive from 2017 until the end of 2025, a tenure that began with the separation of the consumer healthcare business and was defined by a rebuilding of the drug development pipeline. Before that she spent close to two decades at L'Oreal in consumer marketing and general management roles across Europe and Asia, and she ran the group's consumer healthcare division before taking the group chief executive role.
She is not a stranger to the governance of large American technology businesses. Walmsley served for around seven years as a director of Microsoft, which gives her a long view of the enterprise software and devices market that HP sells into, and an existing familiarity with the reporting rhythms and investor expectations of a United States listed technology company.
The appointment also resets the top of the board. Bruce Broussard, the former Humana chief executive who has been serving as HP's interim chief executive since February, becomes Chair of the Board on the same day Walmsley starts. He succeeds Chip Bergh, who has chaired the board since 2017 and joined it in 2015. HP described the board's decision as unanimous.
The context is a business under structural pressure rather than acute distress. HP's two largest franchises pull in different directions. Personal systems has been working through an uneven replacement cycle, with the installed base ageing and a partial, as yet unproven, refresh thesis attached to artificial intelligence capable laptops. Printing, long the higher margin half of the company, faces a slow secular decline in page volumes that cost discipline can soften but not reverse. The strategic question for any incoming chief executive is how much of the printing margin to harvest and how much to reinvest in commercial services, managed print and the enterprise device estate.
Seen in that light, a consumer brand operator with a record of portfolio surgery is a more coherent choice than it first appears. Walmsley's years at the pharmaceuticals group were spent splitting a conglomerate, defending a mature franchise against erosion and arguing an investment case to sceptical shareholders. Those are recognisably the same tasks, in a different industry.
The interim period itself is worth noting. Broussard stepped in at the start of the year and has held the business steady through the search rather than attempting a reset, which is the orderly pattern a board wants when it intends to hand over to a permanent appointment. Moving him to the chair keeps that continuity on the board while giving the incoming chief executive a clear operating mandate.
For Walmsley, this is a second chief executive appointment at the head of a company in a different sector, which is rare at this scale. The market will judge it on whether HP's printing cash flows can be redeployed into growth rather than simply defended, and the first evidence of that will come with the capital allocation and segment guidance set out after she takes the role.
